Pharmacokinetic and pharmacodynamic comparison of two doses of long acting propranolol (80 and 160 mg) in healthy subjects.

Eitemau Tebyg

• Pharmacokinetic and pharmacodynamic studies with long-acting propranolol
  gan: McAinsh, J., et al.
  Cyhoeddwyd: (1978)
• The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension.
  gan: Serlin, M J, et al.
  Cyhoeddwyd: (1983)
• Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.
  gan: Schoors, D F, et al.
  Cyhoeddwyd: (1990)
• Pharmacokinetic and pharmacodynamic interactions between the ACE inhibitor cilazapril and β-adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients
  gan: Belz, G. G., et al.
  Cyhoeddwyd: (1989)
• Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.
  gan: Murdoch, D L, et al.
  Cyhoeddwyd: (1991)